Vaccination of attenuated EIS-producing Salmonella induces protective immunity against enterohemorrhagic Escherichia coli in mice

Vaccine

Volumn 29, Issue 43, 2011, Pages 7395-7403

  Gu, Jiang ^a   Ning, Yuanyuan ^a   Wang, Haiguang ^a   Xiao, Daping ^a   Tang, Bin ^a   Luo, Ping ^a   Cheng, Yan ^a   Jiang, Mingming ^a   Li, Na ^a   Zou, Quanming ^a   Mao, Xuhu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Attenuated Salmonella vaccine; Boost; Enterohemorrhagic Escherichia coli; Protective immunity

Indexed keywords

ESCHERICHIA COLI SECRETED PROTEIN A; ESCHERICHIA COLI SECRETED PROTEIN A INTIMIN VEROTOXIN 2B PRODUCING SALMONELLA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTIMIN; RECOMBINANT PROTEIN; SALMONELLOSIS VACCINE; UNCLASSIFIED DRUG; VEROTOXIN 2; VEROTOXIN 2B;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BACTERIUM CARRIER; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI SECRETED PROTEIN A INTIMIN VEROTOXIN 2B PRODUCING SALMONELLA; FEMALE; LETHAL DOSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SALMONELLA; T LYMPHOCYTE; VACCINATION;

ADHESINS, BACTERIAL; ANIMALS; ANTIBODIES, BACTERIAL; CELL PROLIFERATION; CROSS PROTECTION; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FECES; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LYMPHOCYTES; MICE; SALMONELLA; SALMONELLA VACCINES; SHIGA TOXIN 2; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 80053449345     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.069     Document Type: Article

References (47)

1. Goldwater P.N. Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome. Expert Rev Anti-infect Ther 2007, 5(August (4)):653-663.
2. Riley L.W., Remis R.S., Helgerson S.D., McGee H.B., Wells J.G., Davis B.R., et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983, 308(March (12)):681-685.
3. Wells J.G., Davis B.R., Wachsmuth I.K., Riley L.W., Remis R.S., Sokolow R., et al. Laboratory investigation of hemorrhagic colitis outbreaks associated with a rare Escherichia coli serotype. J Clin Microbiol 1983, 18(September (3)):512-520.
4. Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365(March (9464)):1073-1086.
5. Wong C.S., Jelacic S., Habeeb R.L., Watkins S.L., Tarr P.I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000, 342(June (26)):1930-1936.
6. Orth D., Grif K., Zimmerhackl L.B., Wurzner R. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans. Expert Rev Anti-infect Ther 2008, 6(February (1)):101-108.
7. O'Brien A.D., Holmes R.K. Shiga and shiga-like toxins. Microbiol Rev 1987, 51(June (2)):206-220.
8. Sandvig K., Spilsberg B., Lauvrak S.U., Torgersen M.L., Iversen T.G., van Deurs B. Pathways followed by protein toxins into cells. Int J Med Microbiol 2004, 293(April (7-8)):483-490.
9. Karch H., Tarr P.I., Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005, 295(October (6-7)):405-418.
10. Potter A.A., Klashinsky S., Li Y., Frey E., Townsend H., Rogan D., et al. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 2004, 22(January (3-4)):362-369.
11. Frankel G., Phillips A.D., Rosenshine I., Dougan G., Kaper J.B., Knutton S. Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Mol Microbiol 1998, 30(December (5)):911-921.
12. McDaniel T.K., Jarvis K.G., Donnenberg M.S., Kaper J.B. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc Natl Acad Sci U S A 1995, 92(February (5)):1664-1668.
13. Abe A., Heczko U., Hegele R.G., Brett Finlay B. Two enteropathogenic Escherichia coli type III secreted proteins, EspA and EspB, are virulence factors. J Exp Med 1998, 188(November (10)):1907-1916.
14. Kenny B., Lai L.C., Finlay B.B., Donnenberg M.S. EspA, a protein secreted by enteropathogenic Escherichia coli, is required to induce signals in epithelial cells. Mol Microbiol 1996, 20(April (2)):313-323.
15. Vlisidou I., Dziva F., La Ragione R.M., Best A., Garmendia J., Hawes P., et al. Role of intimin-tir interactions and the tir-cytoskeleton coupling protein in the colonization of calves and lambs by Escherichia coli O157:H7. Infect Immun 2006, 74(January (1)):758-764.
16. Touzé T., Hayward R.D., Eswaran J., Leong J.M., Koronakis V. Self-association of EPEC intimin mediated by the β-barrel-containing anchor domain: a role in clustering of the Tir receptor. Mol Microbiol 2003, 51(1):73-87.
17. Frankel G., Phillips A.D. Attaching effacing Escherichia coli and paradigms of Tir-triggered actin polymerization: getting off the pedestal. Cell Microbiol 2008, 10(March (3)):549-556.
18. Horne C., Vallance B.A., Deng W., Finlay B.B. Current progress in enteropathogenic and enterohemorrhagic Escherichia coli vaccines. Expert Rev Vaccines 2002, 1(December (4)):483-493.
19. Kwon Y.M., Cox M.M., Calhoun L.N. Salmonella-based vaccines for infectious diseases. Expert Rev Vaccines 2007, 6(April (2)):147-152.
20. Sztein M.B. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis 2007, 45(July (Suppl. 1)):S15-S19.
21. Kochi S.K., Killeen K.P., Ryan U.S. Advances in the development of bacterial vector technology. Expert Rev Vaccines 2003, 2(February (1)):31-43.
22. Tacket C.O., Kelly S.M., Schodel F., Losonsky G., Nataro J.P., Edelman R., et al. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun 1997, 65(August (8)):3381-3385.
23. Gu J., Liu Y., Yu S., Wang H., Wang Q., Yi Y., et al. Enterohemorrhagic Escherichia coli trivalent recombinant vaccine containing EspA, intimin and Stx2 induces strong humoral immune response and confers protection in mice. Microbes Infect 2009, 11(September (10-11)):835-841.
24. Nakayama K., Kelly M.S., Curtiss R. Construction of an ASD+ expression-cloning vector: stable maintenance and high level expression of cloned genes in a Salmonella vaccine strain. Nat Biotechnol 1988, 6:693-697.
25. Konjufca V., Wanda S.Y., Jenkins M.C., Curtiss R. A recombinant attenuated Salmonella enterica serovar Typhimurium vaccine encoding Eimeria acervulina antigen offers protection against E. acervulina challenge. Infect Immun 2006, 74(December (12)):6785-6796.
26. Cheng Y., Feng Y., Luo P., Gu J., Yu S., Zhang W.J., et al. Fusion expression and immunogenicity of EHEC EspA-Stx2Al protein: implications for the vaccine development. J Microbiol 2009, 47(August (4)):498-505.
27. Yu S., Gu J., Wang H-G., Wang Q-X., Luo P., Wu C., et al. Identification of a novel linear epitope on EspA from enterohemorrhagic E coli using a neutralizing and protective monoclonal antibody. Clin Immunol 2011, 138(1):77-84.
28. Yong Y., Quanming Z., Jianping C., Xuhu M., Wende T., Ming Z., et al. Construction and prokaryotic expression of the fusion protein Stx2B-intiminC300 of EHEC O157:H7 and it's immunoprophylactic potential. Chin J Microbiol Immunol 2006, 4(02):88.
29. Ma Y., Mao X., Li J., Li H., Feng Y., Chen H., et al. Engineering an anti-Stx2 antibody to control severe infections of EHEC O157:H7. Immunol Lett 2008, 121(December (2)):110-115.
30. Rahn K., De Grandis S.A., Clarke R.C., McEwen S.A., Galan J.E., Ginocchio C., et al. Amplification of an invA gene sequence of Salmonella typhimurium by polymerase chain reaction as a specific method of detection of Salmonella. Mol Cell Probes 1992, 6(August (4)):271-279.
31. Ma B., von Wasielewski R., Lindenmaier W., Dittmar K.E. Immmunohistochemical study of the blood and lymphatic vasculature and the innervation of mouse gut and gut-associated lymphoid tissue. Anat Histol Embryol 2007, 36(February (1)):62-74.
32. Sang H., Pisarev V.M., Chavez J., Robinson S., Guo Y., Hatcher L., et al. Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses. Cancer Gene Ther 2005, 12(April (4)):427-437.
33. Nagano K., Taguchi K., Hara T., Yokoyama S., Kawada K., Mori H. Adhesion and colonization of enterohemorrhagic Escherichia coli O157:H7 in cecum of mice. Microbiol Immunol 2003, 47(2):125-132.
34. Li Y., Frey E., Mackenzie A.M., Finlay B.B. Human response to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors. Infect Immun 2000, 68(September (9)):5090-5095.
35. Dziva F., Vlisidou I., Crepin V.F., Wallis T.S., Frankel G., Stevens M.P. Vaccination of calves with EspA, a key colonisation factor of Escherichia coli O157:H7, induces antigen-specific humoral responses but does not confer protection against intestinal colonisation. Vet Microbiol 2007, 123(July (1-3)):254-261.
36. Marcato P., Griener T.P., Mulvey G.L., Armstrong G.D. Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shiga toxemia. Infect Immun 2005, 73(October (10)):6523-6529.
37. Wen S.X., Teel L.D., Judge N.A., O'Brien A.D. A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc Natl Acad Sci U S A 2006, 103(May (18)):7082-7087.
38. Tsuji T., Shimizu T., Sasaki K., Shimizu Y., Tsukamoto K., Arimitsu H., et al. Protection of mice from shiga toxin-2 toxemia by mucosal vaccine of shiga toxin 2B-His with Escherichia coli enterotoxin. Vaccine 2008, 26(January (4)):469-476.
39. Tsuji T., Shimizu T., Sasaki K., Tsukamoto K., Arimitsu H., Ochi S., et al. A nasal vaccine comprising B-subunit derivative of shiga toxin 2 for cross-protection against shiga toxin types 1 and 2. Vaccine 2008, 26(April (17)):2092-2099.
40. Chin'ombe N., Bourn W.R., Williamson A.L., Shephard E.G. Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice. Virol J 2009, 6:87.
41. Moon J.J., McSorley S.J. Tracking the dynamics of Salmonella specific T cell responses. Curr Top Microbiol Immunol 2009, 334:179-198.
42. Galan J.E. Salmonella interactions with host cells: type III secretion at work. Annu Rev Cell Dev Biol 2001, 17:53-86.
43. Caron E., Crepin V.F., Simpson N., Knutton S., Garmendia J., Frankel G. Subversion of actin dynamics by EPEC and EHEC. Curr Opin Microbiol 2006, 9(February (1)):40-45.
44. Cheng Y., Gu J., Wang H.G., Yu S., Liu Y.Q., Ning Y.L., et al. EspA is a novel fusion partner for expression of foreign proteins in Escherichia coli. J Biotechnol 2010, 150(November (3)):380-388.
45. Curtiss R., Kelly S.M. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun 1987, 55(December (12)):3035-3043.
46. Zhang W.L., Kohler B., Oswald E., Beutin L., Karch H., Morabito S., et al. Genetic diversity of intimin genes of attaching and effacing Escherichia coli strains. J Clin Microbiol 2002, 40(December (12)):4486-4492.
47. Brzuszkiewicz E., Thurmer A., Schuldes J., Leimbach A., Liesegang H., Meyer F.D., et al. Genome sequence analyses of two isolates from the recent Escherichia coli outbreak in Germany reveal the emergence of a new pathotype: entero-aggregative-haemorrhagic Escherichia coli (EAHEC). Arch Microbiol 2011, (June).